Supernus Pharmaceuticals | SUPN - Операционный доход





Операционный доход Изменить Дата
Abbott USD 1.85B 399M 2026-03
ANI Pharmaceuticals USD 29.13M 6.3M 2025-12
Aurora Cannabis CAD -35.79M 19.88M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Canopy Growth CAD -12.66M 1.64M 2025-12
Cara Therapeutics USD -5.94M 3.55M 2025-09
Corcept Therapeutics USD -49.6M 54.09M 2026-03
Eisai JPY 20.03B 6.36B 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Novo Nordisk DKK 32.38B 1.7B 2025-12
Pacira USD 4.62M 1.43M 2026-03
Perrigo USD 84.4M 9M 2025-12
Pfizer USD 4.99B 340M 2026-03
Supernus Pharmaceuticals USD -35.25M 49.07M 2026-03
United Therapeutics USD -14.6M 403.9M 2025-12
Xeris Pharmaceuticals USD 16.77M 10.04M 2025-12